Inflarx Gmbh

Chinese Academy of Medical Sciences

Institute of Pharmacology and Toxicology

Academy of Military Medical Sciences P.l.a.

Institute of Pharmacology and Toxicology Accademy of Military Medical Sciences P.l.a. China

Applied Nanosystems B.v.

Hainan Gt-unipul Pharmaceutical Co. Ltd

Beifen Shen

Yan Li

Shaohua Li

Yu Liu

Niels Christoph Riedemann

Lili Wang

Song Li

Guang Yang

Junhai Xiao

Jie Dong

Renfeng Guo

Liuhong Yun

Hongying Liu

Hongmei Ding

Ming Fan

Zihe Rao

Aihua Nie

Hongxia Wang

Jiahui Yu

Niels Cristoph Riedemann

Guojiang Chen

Xingwei Jiang

Renxi Wang

He Xiao

Chunmei Hou

Zhi Zhao

Ningsheng Shao

Jiannan Feng

Gencheng Han

Yaping Gao

Wuhong Pei

Songcheng Yang

Cuiling Shu

Liqin Zhao

Chuan Liu

The present invention relates to binding moieties that specifically bind to a conformational epitope of C5a, in particular human C5a. Preferred binding moieties are anti-C5a antibodies that bind to this conformational epitope. The binding moieties described herein are useful as active agents in pharmaceutical compositions for the treatment and prevention of various acute and chronic diseases, in particular acute inflammatory diseases, such as the systemic inflammatory response syndrome (SIRS), and different degrees of sepsis including sepsis, severe sepsis, and septic shock.

Anti-C5a binding moieties with high blocking activity

The present invention provides a human Tim-3-Ig fusion protein which can block Tim-3 signal pathway, and said Ig fusion protein comprises Tim-3 protein, human Ig fragment, and the linking sequence therebetween. In the present invention, a human Tim-3-Ig gene is obtained by an artificial synthesis process; an expression vector containing the Tim-3-Ig gene is constructed; and the prepared Ig fusion protein is tested in an expression verification experiment, a binding activity experiment, a blocking activity experiment in different cell lines, and in vivo experiments in mice. The human Tim-3-Ig fusion protein prepared in the present invention can be used to treat immunological diseases caused by high expression of Tim-3.

Human Tim-3 fusion protein capable of blocking Tim-3 signaling pathway

Anti-C5A binding moieties with high blocking activity

Anti-C5a binding antibodies with high block activity

This invention relates to substituted 6-membered N-Herterocyclic neurotrophic compounds of formula (I) or pharmaceutically acceptable salts or hydrates thereof, wherein R, R, X, Y, and Z are as defined in the description; their preparation methods, compositions comprising the same, and their use as inhibitors of FK560 binding proteases activity for treating and preventing neurodegenerative diseases and other nerve disorders associated with nerve injuries or other related diseases 

Substituted 6-membered N-heterocyclic compounds and method for their use as neurological regulator

This invention relates to substituted 5-membered N-Herterocyclic neurotrophic compounds of formula (I) or pharmaceutically acceptable salts or hydrates thereof, wherein R, R, R, R, V, W, X, Y, and Z are as defined in the description; their preparation methods, compositions comprising the same, and their use as inhibitors of FK560 binding proteases (FKBPs) activity for treating and preventing neurodegenerative diseases and other nerve disorders associated with nerve injuries or other related diseases. 

Substituted 5-membered n-heterocyclic compounds and their uses for treating or preventing neurodegenerative diseases

Growing community of inventors

Beijing, China

Beifen Shen